法尼甾体X受体
肝肠循环
FGF19型
胆汁酸
G蛋白偶联胆汁酸受体
胆固醇7α羟化酶
CYP8B1
肠促胰岛素
2型糖尿病
医学
肠道菌群
生物
内科学
葡萄糖稳态
炎症
内分泌学
药理学
生物化学
受体
核受体
成纤维细胞生长因子
糖尿病
胰岛素抵抗
转录因子
基因
作者
Tiangang Li,John Y.L. Chiang
出处
期刊:Current Opinion in Gastroenterology
[Ovid Technologies (Wolters Kluwer)]
日期:2015-03-01
卷期号:31 (2): 159-165
被引量:223
标识
DOI:10.1097/mog.0000000000000156
摘要
This review focuses on the latest understanding of the molecular mechanisms underlying the complex interactions between intestine and liver bile acid signaling, gut microbiota, and their impact on whole-body lipid, glucose and energy metabolism.Hepatic bile acid synthesis is tightly regulated by the bile acid negative feedback mechanisms. Modulating the enterohepatic bile acid signaling greatly impacts the whole-body metabolic homeostasis. Recently, a positive feedback mechanism through intestine farnesoid X receptor (FXR) antagonism has been proposed to link gut microbiota to the regulation of bile acid composition and pool size. Two studies identified intestine Diet1 and hepatic SHP-2 as novel regulators of CYP7A1 and bile acid synthesis through the gut-liver FXR-fibroblast growth factor 15/19-FGF receptor four signaling axis. New evidence suggests that enhancing bile acid signaling in the distal ileum and colon contributes to the metabolic benefits of bile acid sequestrants and bariatric surgery.Small-molecule ligands that target TGR5 and FXR have shown promise in treating various metabolic and inflammation-related human diseases. New insights into the mechanisms underlying the bariatric surgery and bile acid sequestrant treatment suggest that targeting the enterohepatic circulation to modulate gut-liver bile acid signaling, incretin production and microbiota represents a new strategy to treat obesity and type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI